Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Any progress wrt the covid19 treatment?
A solid start to the day for TRVN $5.00 he we come, the placement people are all happy and might decide to add on to the winner.
I do a lot of chart studying. Not a pure technical trader, but I use volume bands and news as a guide. These is a lot of previous volume/resistance where the pullback occurred. Plus, after all the presentations were over, thee is usually a pullback.
I don't think we will break past that resistance until reasonable revenue growth is demonstrated. Maybe next quarter. Or more good news of some type.
All this is educated guesswork.
Nice call Herbie on the pullback I bot back those shares I sold at 3.06 under 2.70 the golf trip is on TRVN dime now.Have a great day. I dont post much but if u look at the only stock that I post about its a cheapy and it should be getting very hot.
* * $TRVN Video Chart 09-23-2020 * *
Link to Video - click here to watch the technical chart video
Its all good.
Sold 50% of shares. Will get back in if a pullback to around $2.60.
Looking for some other opportunities which are depressed right now.
GL!
Well Herbie you got your target of 3.00. I sold a few thousand shares @ 3.06 for some golf trip money for me and my boys my treat. Holding the size for the run up to $5.00
Nice going Herbie stay strong and long................
Are you saying my CELH from .20 to 26.00$ was a scam come on man it was gold. Also I had a huge position there and still hold a good size position
Still holding on to my $1.63 shares. Ready to sell half up here around expected resistance @ approx $3.00. Expecting a pullback there. We'll see!
I'll also have fresh powder soon to buy even more on a pullback. Also looking at some others that have pulled back like TRVN did.
Its all good. GLTA
Nice pick on this one. The other one is a scam. This is how you make money on this real one
Thats the way big money is made with TRVN.Still sitting with 60000 shares from under 1.60. With a 5.00 target which should come pretty soon
* * $TRVN Video Chart 09-21-2020 * *
Link to Video - click here to watch the technical chart video
TRVN $ Took some profit on 20k that I bot from under 1.60 . Above 2.70 still have plenty more for the long term hold.
News; $TRVN Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting
-- Live presentation highlighting TRV027 as a potential treatment for COVID-19 acute respiratory distress syndrome (ARDS) / abnormal clotting Posters on OLINVYK benefit-risk profile and TRV250 Phase 1 pharmacokinetics -- ...
Read the whole news TRVN - Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting
Breaking News: $TRVN Making A List Of Penny Stocks To Buy? 4 Gaining Attention In September
Are These On Your List Of Penny Stocks To Buy This Week? Have you made your list of penny stocks this week? If you haven’t and are just getting things started, you’ve got your work cut out. There’ve been a lot of discussions over the weekend on what to focus on this week...
Find out more TRVN - Making A List Of Penny Stocks To Buy? 4 Gaining Attention In September
* * $TRVN Video Chart 09-18-2020 * *
Link to Video - click here to watch the technical chart video
I'm looking far past the target, betting on price moves in anticipation of 2025 sales. Having experience with other small bios, I'm hoping they get a sales plan or partner or sell to a large bio with sales experience.
GLTA
$5.00 target longs have made a smart move when they bought under 1.60. Im havent sold a share from the buys under 1.60 those should be gold in a couple of months they are silver right now lol. The flippers are gone they took a beating. Stay strong and hold. stock went on discount sale under $2.00.
Relatively new to this board and TRVN. I waited for some "confirmation" and got in at $1.63 average. I'm a long holder. I have to wait to get some fresh powder then get in more on a dip next week.
Another good day here just like I said it would when we traded down to 1.50. I hope other true longs were able to buy down there it was a gift.
I stand by my words " I really dont see any problems getting back up to the placement price." and here we are. $$$$$$
TRVN Rebound in full swing here~
Breaking News: $TRVN Why Shares of Trevena Blasted Nearly 17% Higher on Monday
Shares of Trevena (NASDAQ: TRVN) shot higher on Monday following a very bullish analyst report. Guggenheim initiated coverage on the stock, with prognosticator Dana Flanders rating it a buy with a price target of $5.00. Even after Monday's price hike, that level still implies potential upsid...
Read the whole news TRVN - Why Shares of Trevena Blasted Nearly 17% Higher on Monday
NEWS: $TRVN Looking For Top Penny Stocks To Buy Today? 4 To Watch Closely
Are These Top Penny Stocks To Buy Or Avoid Today? The price of penny stocks can shift in an instant as many of you already know. This is one of the top reasons that these cheap stocks garner so much attention. What’s more, is that so many of these companies tend to captivate interest ...
Got this from TRVN - Looking For Top Penny Stocks To Buy Today? 4 To Watch Closely
LMAO....nice close
* * $TRVN Video Chart 09-14-2020 * *
Link to Video - click here to watch the technical chart video
*Trecena shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and a price target of $5 per share.
nice pop today my buys under 1.60 are looking very smart today
Trevena Loses Bid to End Shareholder Lawsuit Over Drug Approval
Sept. 1, 2020, 3:15 AM
Suit claims Trevena misled investors about conversations with FDAJudge dismisses some conclusory allegations against chief medical officer
Trevena, Inc. will have to continue litigating with shareholders over its recently approved morphine alternative oliceridine, now marketed as Olinvyk, after a district court largely denied or otherwise declined to consider the defendants’ motions to dismiss.
The U.S. District Court for the Eastern District of Pennsylvania on Friday denied Trevena and former chief executive officer Maxine Gowen’s motions to dismiss after striking documents integral to their arguments. Judge Cynthia M. Rufe did, however, consider and grant some of former chief medical David Soergel’s motion to dismiss.
https://news.bloomberglaw.com/class-action/trevena-loses-bid-to-end-shareholder-lawsuit-over-drug-approval
42 million shares traded in one day!!!!!!
* * $TRVN Video Chart 08-28-2020 * *
Link to Video - click here to watch the technical chart video
Massive volume today. Small bio-techs with solid FDA approved drugs
without a sales force should be acquired by larger companies that have
an already established (and paid for) sales force. New medications
do not just sell themselves...potential new users of the product have
to be educated on the advantages that the new product offers.
I am out for now and be back later
Analyst Actions: Cantor Fitzgerald Starts Trevena at Overweight With $5 Price Target
BY MT Newswires
— 6:48 AM ET 08/28/2020
06:48 AM EDT, 08/28/2020 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
Price: 1.7400, Change: +0.17, Percent Change: +10.83
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
$TRVN new article!
https://insiderfinancial.com/trevena-stock-forecast-new-highs-ahead/180322/
Absolutely a gift.. Pre-market high $1.82. Now $1.80 at 6:52 a.m.
Very good to see this It was a major buy in the 1.50 zone I took advantage of the price. I am now at my full position. I really dont see any problems getting back up to the placement price.
Trevena initiated with an Overweight at Cantor Fitzgerald
the fly released the target price
16:05 TRVN Cantor Fitzgerald analyst Brandon Folkes initiated coverage of Trevena with an Overweight rating and $5 price target.
Read more at:
https://thefly.com/n.php?id=3152661
I bought bunch of $1.5 today. It is a gift
$TRVN Trevana announced two publications of the respiratory safety data from the OLINVYK development program
7:04 AM ET 8/26/20 | Briefing.com
Related Quotes
4:00 PM ET 8/27/20
Symbol Last % Chg
TRVN
1.57 2.61%
Real time quote.
Study Summary and Key Findings:
OLINVYK was associated with a higher probability of analgesia than respiratory depression, while the reverse was true for morphine.
The clinical utility function model predicted there would be a lower probability of a respiratory event occurring with OLINVYK versus morphine.
From Market Beat:
Trevena (NASDAQ:TRVN) is now covered by analysts at Cantor Fitzgerald (star star star blank star blank star). They set an "overweight" rating on the stock. current price of $1.58.
Trevena Announces Publications of OLINVYK™ Respiratory Safety Analyses vs. IV Morphine
BY GlobeNewswire
— 7:00 AM ET 08/26/2020
--
Publication in Anesthesiology: Favorable benefit-risk profile for OLINVYK (oliceridine) injection as measured by clinical utility function analysis
Publication in Clinical Drug Investigation: Lower incidence of respiratory depression associated with OLINVYK as measured by frequency / duration of dosing interruption
--
CHESTERBROOK, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. ( TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two publications of the respiratory safety data from the OLINVYK development
program. Both publications highlight data showing an improved respiratory safety profile for OLINVYK compared to IV morphine.
And more.............
Public offering 50M to raise capital
* * $TRVN Video Chart 08-24-2020 * *
Link to Video - click here to watch the technical chart video
Very good to see this today. Very good to have bought shares @1.65.Should have no problem getting up to 2.30 in a few days.
NEWS OUT!
Trevena Announces Initiation of TRV027 Study in COVID-19 Patients in Collaboration With Imperial College London
BY GlobeNewswire
— 7:00 AM ET 08/24/2020
CHESTERBROOK, Pa., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced Imperial College London (ICL) has initiated a proof-of-concept study for TRV027 in COVID-19 patients. Through an ongoing collaboration with ICL, the Company is evaluating the potential of TRV027 to treat acute lung damage / abnormal blood clotting associated with COVID-19. ICL is sponsoring and funding the study, with additional support through the British Heart Foundation Centre for Research Excellence Award.
“I am very pleased that Imperial College London has reached this important milestone of trial initiation,” said Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. (TRVN) “As the global search for solutions to combat the COVID-19 pandemic continues, there remains an urgent need for new therapies that can prevent the severe multi-organ damage caused by the virus. TRV027 represents a uniquely targeted approach to potentially treating some of the serious and deadly complications associated with COVID-19.”
In a COVID-19 infection, the SARS-coronavirus-2 binds to and removes the ACE2 protein in the lungs and other organs, resulting in a hormonal imbalance at the AT1 receptor. This results in acute lung damage, which often progresses to acute respiratory distress syndrome (ARDS), as well as abnormal blood clotting throughout the body. TRV027 specifically binds to and rebalances AT1 receptor activation, blocking the damaging pathway that leads to ARDS and abnormal blood clotting conditions such as stroke. Additionally, the unique mechanism of action of TRV027 selectively targets the reparative pathway that improves lung function and promotes anti-inflammatory effects.
This is a randomized, double-blind, placebo-controlled study that will enroll approximately 60 hospitalized, non-ventilated patients aged 18 or older with a confirmed COVID-19 infection. The primary objective of the study is to evaluate whether TRV027 reduces abnormal clotting associated with COVID-19. The study will also assess the effect of TRV027 on lung function and other clinical outcomes. The Company currently expects to report topline data in Q1 2021.
Followers
|
108
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1326
|
Created
|
06/29/14
|
Type
|
Free
|
Moderators |
Trevena, Inc. (NASDAQ: TRVN) is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders.
The company has five novel and differentiated drug development programs. OLINVYK™ is approved by the FDA. Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com.
The company has four investigational drug candidates including TRV 027 for acute respiratory distress syndrome and abnormal clotting, TRV 250 for the acute treatment of migraine and TRV 734 for maintenance treatment of opioid use disorder. The company has also identified TRV 045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain and CNS disorders.
Trevena is guided by an innovative spirit and an unwavering commitment to patients. It is a place driven by its employees – passionate and talented industry experts who operate with integrity, transparency, and respect for one another. Trevena employees are united in one mission: to deliver new medicines that address critical areas of need in CNS disorders.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |